TrialHaematologica2024

Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study.

Evangelos Terpos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.